SCHEMBL7190202

SCHEMBL7190202

COP(=O)(OC)c1cc(-c2ccc(C)cc2)ccc1OCC=C(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 1/20 0.40
▸ MTNR1A P48039 1/20 0.40
▸ PTGES O14684 4/20 0.39
▸ PDE4B Q07343 4/20 0.38
▸ MAOB P27338 1/20 0.36
▸ ALOX5 P09917 2/20 0.36
▸ PDE4A P27815 2/20 0.36
▸ PDE4C Q08493 2/20 0.36
▸ PDE4D Q08499 2/20 0.36
▸ MGAM O43451 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ SI P14410 1/20 0.36
▸ MGAM2 Q2M2H8 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ CASP1 P29466 1/20 0.35
▸ CASP7 P55210 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7190208 0.82 ALDH1A1 (0.41) TRPA1MTNR1APTGESPDE4BMAOB
SCHEMBL7188341 0.79 PTPN11 (0.40) GAAKDM4EALDH1A1CYP3A4
SCHEMBL7527196 0.78 ALDH1A1 (0.43) ALOX5KDM4EALDH1A1CYP3A4HPGD
SCHEMBL7188818 0.78 CFD (0.45) MAOBGAAKDM4EALDH1A1HPGD
SCHEMBL7182874 0.76 GAK (0.38) MGAMGAASIMGAM2KDM4E
SCHEMBL7195829 0.73 MGAM (0.37) PDE4BPDE4APDE4CPDE4DMGAM
SCHEMBL7191478 0.72 HPGD (0.39) PTGESALOX5KDM4EALDH1A1HPGD
SCHEMBL7183095 0.72 MCL1 (0.47) TRPA1KDM4EALDH1A1HPGD
SCHEMBL7183230 0.68 PTPN5 (0.36) ALDH1A1HPGD
SCHEMBL14511893 0.67 PDE4A (0.52) TRPA1MTNR1APTGESPDE4BMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268494-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS Merck Frosst Canada & Co. (CA) 2003-01-02 — — EP disclosed
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 — — US disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 — — US disclosed
WO-2001070753-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO TRPA1 1833/4885MTNR1A 1559/4885PTGES 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback